Insulet’s Omnipod 5 automated insulin delivery system was shown to be effective, safe, and easy to use for adults, teens, and children with type 1 diabetes. Early...

Michael writes about how he used two main strategies – intermittent fasting and walking after meals ­– to put his type 2 diabetes into remission

Diabeloop’s AID system can improve Time in Range and quality of life for people with type 1 diabetes. Read below to learn more.

The recent release of clinical trial results shows that Omnipod 5, an automated insulin delivery (AID) system, can significantly increase Time in Range and reduce stress...

Results from recent clinical trials have shown that GLP-1 receptor agonist medications are effective at lowering A1C and body weight.

diaTribe is excited to bring you additional expanded coverage from the EASD 2021 virtual conference this past week! Find out more from leading clinicians and researchers...

diaTribe partnered with Abbott and Novo Nordisk to bring you the Time in Range Hub – a new online resource to help you and your healthcare providers learn about Time in...

Studies show that if you have diabetes, increasing your Time in Range (TIR) can lower your risk of developing kidney disease. Learn how kidney disease is diagnosed, why...

Quality measures are tools to evaluate the effectiveness and quality of healthcare. Measures such as A1C, blood pressure, and cholesterol are used to understand health...

A survey jointly conducted by diabetes research company dQ&A and The diaTribe Foundation assessed how well endocrinologists understood Time in Range and which...

Julie Heverly describes one harrowing day when her glucose levels teetered between way too high and way too low and how she navigated this challenge.

diaTribe’s Community Manager Cherise Shockley led an online discussion about Time in Range with Shay Webb, a diabetes advocate, and Julia Blanchette, a diabetes care and...

The Association of Diabetes Care and Education Specialists 2021 conference covered the impacts of diabetes stigma, smart MDI therapies, insulin delivery by means other...

The artificial pancreas is here for those willing to build their own; what can manufacturers learn from OpenAPS?

Strong results from the IMPACT study in low-A1c users.

Highlights from the first study of a commercial automated insulin delivery device. Plus, Medtronic’s latest software updates!

What does A1c miss and what can we do about it?

Coming to US in Spring 2017: What it is, what it isn’t, and how to get it

How many people have type 1? What are the barriers to using new therapies? What outcomes matter beyond A1c?

Tripling my carbs --> 5 fewer hours in-range per day, 64% more insulin (!), & more lessons learned.